A Study of Comorbidities in Association With Covid-19 Positive Patients.

Background: Many researchers have noted the higher mortality rate of COVID-19 infections in subjects with comorbidities such as hypertension, cardiovascular disease, obesity, diabetes, and cancer. Further predisposing conditions are chronic kidney disease, chronic lung diseases like asthma, neurological conditions like dementia, liver diseases, solid organ transplant, chronic respiratory disease, Down syndrome, immunocompromised individuals, autoimmune diseases, those on long term steroid and immunomodulatory treatment and alcohol consumption. Method: This study was a cross sectional analytical study conducted on Covid-19 Positive inpatients at Medicine Department, CHA from September 2020 to August 2021. Result: Comparison was done between patients with comorbidities(group A) and without co-morbidities(group B) and it was found that presenting complaints like sputum production and dysnoea as well as severity of the disease was more in group Apatients. Biochemical parameters such as (S. creatinine (mg/dL) and D-Dimer (µg/l)), duration of hospital Stay (day) were found statistically signicant between the two groups(p<0.0001). Higher severity of disease and mortality rate was found in group A. Conclusion:As a conclusion, pneumonialike symptoms were seen by a broad population worldwide as a result of SARS-CoV-2, and individuals with comorbidities are particularly at risk of contacting the virus. Higher mortality risks were associated with co-infected individuals with COVID-19, including those who have HTN and IHD. However, other comorbidities like diabetes, diseases of the lower respiratory tract, and problems with the liver and kidneys may further aggravate the severity of COVID-19. As our study was carried out during early phase of pandemic comordity like mucormycosis was not observed in our patients. The comorbid people must take diligent precautions like vaccination and other personal protective equipments to safeguard themselves throughout the pandemic.